The case for & against
Bull & Bear analysis
Journey Medical, Inc. (NASDAQ: JRNY) is a leader in the biopharmaceutical sector, focused on developing and commercializing innovative dermatology products, particularly for inflammatory skin conditions like rosacea. The company is poised to capitalize on the introduction of its promising oral treatment, MROSI, which aims to address significant unmet needs in dermatology. As a player in the highly competitive therapeutic landscape, Journey Medical is leveraging recent clinical successes and market access strategies to drive sales growth and ultimately position itself for increased market share.
Bull says
- ↑Q3 2025 net sales $17.6M (+21% YoY), led by MROSI uptake
- ↑MROSI scripts +75% sequentially with 1:1 refill ratio
- ↑Covered 100M of 187M commercial lives; strong GPO traction
- ↑Operating expenses +9% YoY vs. 21% revenue growth
- ↑Management projects peak net sales >$200M U.S. and >$300M global
- ↑Strong liquidity, low leverage risk and healthy balance sheet
Bear says
- ↓2024 net product revenue declined to $55.1M from $59.7M
- ↓Net loss surged to $14.7M vs. $3.9M prior year
- ↓Negative earnings yield and weak analyst revisions signal risk
- ↓Payer coverage delays could extend MROSI ramp-up 12–18 months
- ↓High rebate costs eroding legacy product margins
- ↓Elevated short interest and small‐cap vulnerability heighten skepticism
Investment themes with FBIO
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q4 2024 · Mgmt. Guidance
Transcript signals
Bull points
- As far as capital allocation, you know, we're good with cash. You know, we're very comfortable with our cash at this point.
- The fact is, you know, those brands do have their – competitive generics out there, especially with TargetOx. So, you know, there's some erosion in the volume of the scripts, more so than it is a pricing game with that. The one benefit is, too, with ExelDerm is we no longer have the obligation of paying royalties, so our margins for that product have actually gotten better.
- 2024 was a pivotal year for Journey Medical as we delivered on all of our guidance ranges for the year and positioned the company to launch MROSI, our best-in-class oral treatment for rosacea.
Bear points
- Our total net product revenue in 2024 was $55.1 million, which compares to the $59.7 million that were reported in 2023. The decrease was primarily due to overall higher rebate costs across our product portfolio and lower unit volumes, mainly from our legacy products.
- Net loss to common shareholders was $14.7 million, or 72 cents per share basic and diluted for the full year 2024. This compares to a net loss to common shareholders of $3.9 million, or 21 cents per share basic and diluted for the full year of 2023.
- Our total net product revenue in 2024 was $55.1 million, which compares to the $59.7 million that were reported in 2023. The decrease was primarily due to overall higher rebate costs across our product portfolio and lower unit volumes, mainly from our legacy products.